ProMIS Neurosciences to Present Preclinical Data on Alzheimer’s Disease Therapeutic Antibody PMN310 at Alzheimer’s Association International Conference PMN310 Shows Potential for Best in Class Amyloid-Beta Oligomer Selectivity TORONTO, Ontario and CAMBRIDGE, Massachusetts – July 10, 2018– ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery…
ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders ProMIS’ shareholders show overwhelming support for all resolutions TSX:PMN; OTCQB: ARFXF TORONTO, ON and CAMBRIDGE, MA, June 28, 2018 – ProMIS Neurosciences, Inc. (the “Corporation”), a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today…
ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases Antibody Candidates Targeting Toxic Oligomers Implicated in Parkinson’s Disease and Amyotrophic Lateral Sclerosis (ALS) Advance to the Final Stage of ProMIS Discovery Platform TSX:PMN; OTCQB: ARFXF TORONTO, ONTARIO and CAMBRIDGE, MA – June 26, 2018 – ProMIS…
News Release ProMIS Neurosciences Reminds Shareholders of June 25th Voting Cut-Off for Upcoming Annual General Meeting TORONTO, ONTARIO and CAMBRIDGE, MA – June 20, 2018 – ProMIS Neurosciences Inc. (the “Corporation”) (TSX: PMN.TO) (OTCQB: ARFXF) would like to remind shareholders they have until 9:00 am (Toronto Time) on Monday June…
ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer’s Disease Program is on track for clinical trial start in H2 2019 TORONTO, ONTARIO and CAMBRIDGE, MA – June 12, 2018 – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision…
ProMIS Neurosciences Announces First Quarter 2018 Results TORONTO, ONTARIO and CAMBRIDGE, MA –May 11, 2018 – ProMIS Neurosciences Inc. (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the three months ended March…
